Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis

Abrocitinib is a JAK1 selective inhibitor recently approved for the treatment of moderate-to-severe atopic dermatitis in adults. It has demonstrated efficacy and safety in several clinical trials, both in children and adults, in monotherapy, and compared with dupilumab. The expected EASI-75 response...

Descripción completa

Detalles Bibliográficos
Autores principales: Iznardo, Helena, Roé, Esther, Serra-Baldrich, Esther, Puig, Lluís
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960033/
https://www.ncbi.nlm.nih.gov/pubmed/36839707
http://dx.doi.org/10.3390/pharmaceutics15020385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960033/
https://www.ncbi.nlm.nih.gov/pubmed/36839707
http://dx.doi.org/10.3390/pharmaceutics15020385

Ejemplares similares